FdaApplication
NDA 050126
Identifiers
- fda_app_no: NDA050126
Properties
| Property | Value |
|---|---|
| applicant_name | WYETH AYERST LABORATORIES |
| application_type | NDA |
Revenue by product
BICILLIN
| Period | Revenue |
|---|---|
| Q4 2023 | $24.0M |
| Q3 2023 | $37.0M |
| Q2 2023 | $53.0M |
| Q4 2022 | $38.0M |
| Q3 2022 | $36.0M |
| Q2 2022 | $48.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BICILLIN | PENICILLIN G BENZATHINE | 300,000 UNITS/5ML | SUSPENSION;ORAL |
1 product